About this trial
This clinical investigation is intended to demonstrate safety and effectiveness of the PulseMagic™ TrueForce™ Ablation Catheter and the PulseMagic™Pulse Field Ablation (PFA) Generator, and Columbus™ 3D EP Navigation System with Pulsed Field Ablation Software for the treatment of symptomatic, recurrent, drug refractory paroxysmal atrial fibrillation (PAF).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged ≥ 18 years old.
Clinically diagnosed with symptomatic paroxysmal atrial fibrillation.
Atrial fibrillation documented by surface electrocardiogram (ECG), or ambulatory electrocardiogram (including single-lead ECG recorder).
Poor response or intolerance to at least one Class I or Class III antiarrhythmic drug.
Disqualifiers
Patients with a history of atrial fibrillation ablation.
Left atrial thrombus.
Left atrial anteroposterior diameter ≥ 60 mm, and left ventricular ejection fraction (LVEF) ≤ 40%.
Patients with active implantable devices in situ (e.g., cardiac pacemaker, ICD, etc.).
Trial design
Single group
Treatments tested in this trial
PFA Ablation catheter
DeviceDeliver PF energy using the PulseMagic™ PFA system
Treatment groups
Trial outcomes
Primary outcomes
The success rate within 12 months after operation treatment without AADs
Freedom from documented (symptomatic or asymptomatic) AF/AFL/AT episodes of greater than 30 seconds duration that are documented by protocol-specified 12-lead ECG, TTM or Holter monitor (HM) devices after the index ablation procedure
Secondary outcomes
Acute procedural success
Acute procedural success is defined as the isolation of each PV after a 20 min observation period following the last ablation.
Primary safety endpoint
The incidence of primary adverse events refers to the rate of early-onset adverse events occurring within 7 days after ablation, including: vagal reflex complicated with severe bradycardia, acute coronary injury/occlusion, acute kidney injury, myocardial infarction, phrenic nerve injury/paralysis, left atrial-esophageal fistula, transient ischaemic attack, stroke/cerebrovascular accident/thromboembolism, pericarditis requiring intervention, cardiac tamponade/perforation, pneumothorax, severe vascular access complications and death.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: